StreetInsider.com News Articles

Insmed (INSM) Reiterated at Buy by Stifel After TPIP P2b Trial Data

Fri, 17 Jul 2026 07:20:53 -0400

Stifel analyst Stephen Willey reiterated a Buy rating and $200.00 price target on Insmed (NASDAQ: INSM).

The analyst commented, "We believe TPIP data from the 12-month open-label extension (OLE) portion of the P2b trial reinforce the best-inclass TPIP-mediated clinical benefit observed in the placebo-controlled randomized portion of the trial and suggest a continued depth/durability of clinical benefit (across a spectrum of endpoints) which serves to de-risk the registrational P3 development effort. While acknowledging OLE data and the inherent variability associated with disease-specific endpoints can be challenging to adjudicate in the absence of a placebo control, we believe the magnitude and consistency

Insmed reports 12-month OLE data for TPIP in PAH patients

Thu, 16 Jul 2026 07:02:08 -0400

Insmed Incorporated (Nasdaq: INSM) released 12-month data from an ongoing open-label extension (OLE) study evaluating treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension (PAH), according to a company statement issued July 16, 2026.

The 24-month OLE study enrolled 91 patients across 45 global sites. At month 12, patients in the TPIP Continued group (N=60) showed a mean improvement in six-minute walk distance of +55.7 meters from baseline, while the Placebo Crossed group (N=31) showed +54.1 meters. NT-proBNP concentration was reduced by approximately 60% in both groups. WHO Functional Class I or II was achieved in 78.3% of the

Insmed reports 12-month OLE data for TPIP in PAH patients

Thu, 16 Jul 2026 07:02:08 -0400

Insmed reports 12-month OLE data for TPIP in PAH patients

Thu, 16 Jul 2026 07:02:08 -0400

Insmed reports 12-month OLE data for TPIP in PAH patients

Thu, 16 Jul 2026 07:02:08 -0400

Form 8-K INSMED Inc For: Jul 16

Thu, 16 Jul 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260716/26776495.html

Form 8-K INSMED Inc For: Jul 16

Thu, 16 Jul 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260716/26776495.html

Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension

Thu, 16 Jul 2026 07:00:00 -0400

–12-Month Data Demonstrated Sustained Improvement with TPIP Across All Secondary Efficacy Measures Including Reduction in Mortality Risk Status by REVEAL Lite 2.0–

–Placebo Crossed Group Demonstrated Treatment Response on TPIP, Achieving Similar Outcomes to the TPIP Continued Group by Month 12–

–TPIP Was Safe and Well-tolerated with No Newly Identified Safety Signals through Month 12; Doses Up to 1,280 µg Once Daily Were Permitted in the OLE Study–

–These OLE Data, Combined with Once-Daily Inhaled Administration, Reinforce TPIP's Potential to Become the Prostanoid of Choice for Patients with PAH–

–Insmed to Host Investor Call

Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension

Thu, 16 Jul 2026 07:00:00 -0400

–12-Month Data Demonstrated Sustained Improvement with TPIP Across All Secondary Efficacy Measures Including Reduction in Mortality Risk Status by REVEAL Lite 2.0–
–Placebo Crossed Group Demonstrated Treatment Response on TPIP, Achieving Similar Outcomes to the TPIP Continued Group by Month 12–
–TPIP Was Safe and Well-tolerated with No Newly Identified Safety Signals through Month 12; Doses Up to 1,280 µg Once Daily Were Permitted in the OLE Study–
–These OLE Data, Combined with Once-Daily Inhaled Administration, Reinforce TPIP's Potential to Become the Prostanoid of Choice for Patients with PAH–
–Insmed to Host Investor Call

Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension

Thu, 16 Jul 2026 07:00:00 -0400

–12-Month Data Demonstrated Sustained Improvement with TPIP Across All Secondary Efficacy Measures Including Reduction in Mortality Risk Status by REVEAL Lite 2.0–
–Placebo Crossed Group Demonstrated Treatment Response on TPIP, Achieving Similar Outcomes to the TPIP Continued Group by Month 12–
–TPIP Was Safe and Well-tolerated with No Newly Identified Safety Signals through Month 12; Doses Up to 1,280 µg Once Daily Were Permitted in the OLE Study–
–These OLE Data, Combined with Once-Daily Inhaled Administration, Reinforce TPIP's Potential to Become the Prostanoid of Choice for Patients with PAH–
–Insmed to Host Investor Call

Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension

Thu, 16 Jul 2026 07:00:00 -0400

–12-Month Data Demonstrated Sustained Improvement with TPIP Across All Secondary Efficacy Measures Including Reduction in Mortality Risk Status by REVEAL Lite 2.0–
–Placebo Crossed Group Demonstrated Treatment Response on TPIP, Achieving Similar Outcomes to the TPIP Continued Group by Month 12–
–TPIP Was Safe and Well-tolerated with No Newly Identified Safety Signals through Month 12; Doses Up to 1,280 µg Once Daily Were Permitted in the OLE Study–
–These OLE Data, Combined with Once-Daily Inhaled Administration, Reinforce TPIP's Potential to Become the Prostanoid of Choice for Patients with PAH–
–Insmed to Host Investor Call

Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension

Thu, 16 Jul 2026 07:00:00 -0400

–12-Month Data Demonstrated Sustained Improvement with TPIP Across All Secondary Efficacy Measures Including Reduction in Mortality Risk Status by REVEAL Lite 2.0–
–Placebo Crossed Group Demonstrated Treatment Response on TPIP, Achieving Similar Outcomes to the TPIP Continued Group by Month 12–
–TPIP Was Safe and Well-tolerated with No Newly Identified Safety Signals through Month 12; Doses Up to 1,280 µg Once Daily Were Permitted in the OLE Study–
–These OLE Data, Combined with Once-Daily Inhaled Administration, Reinforce TPIP's Potential to Become the Prostanoid of Choice for Patients with PAH–
–Insmed to Host Investor Call

Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension

Thu, 16 Jul 2026 07:00:00 -0400

–12-Month Data Demonstrated Sustained Improvement with TPIP Across All Secondary Efficacy Measures Including Reduction in Mortality Risk Status by REVEAL Lite 2.0–
–Placebo Crossed Group Demonstrated Treatment Response on TPIP, Achieving Similar Outcomes to the TPIP Continued Group by Month 12–
–TPIP Was Safe and Well-tolerated with No Newly Identified Safety Signals through Month 12; Doses Up to 1,280 µg Once Daily Were Permitted in the OLE Study–
–These OLE Data, Combined with Once-Daily Inhaled Administration, Reinforce TPIP's Potential to Become the Prostanoid of Choice for Patients with PAH–
–Insmed to Host Investor Call

Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension

Thu, 16 Jul 2026 07:00:00 -0400

–12-Month Data Demonstrated Sustained Improvement with TPIP Across All Secondary Efficacy Measures Including Reduction in Mortality Risk Status by REVEAL Lite 2.0–
–Placebo Crossed Group Demonstrated Treatment Response on TPIP, Achieving Similar Outcomes to the TPIP Continued Group by Month 12–
–TPIP Was Safe and Well-tolerated with No Newly Identified Safety Signals through Month 12; Doses Up to 1,280 µg Once Daily Were Permitted in the OLE Study–
–These OLE Data, Combined with Once-Daily Inhaled Administration, Reinforce TPIP's Potential to Become the Prostanoid of Choice for Patients with PAH–
–Insmed to Host Investor Call

Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension

Thu, 16 Jul 2026 07:00:00 -0400

–12-Month Data Demonstrated Sustained Improvement with TPIP Across All Secondary Efficacy Measures Including Reduction in Mortality Risk Status by REVEAL Lite 2.0–
–Placebo Crossed Group Demonstrated Treatment Response on TPIP, Achieving Similar Outcomes to the TPIP Continued Group by Month 12–
–TPIP Was Safe and Well-tolerated with No Newly Identified Safety Signals through Month 12; Doses Up to 1,280 µg Once Daily Were Permitted in the OLE Study–
–These OLE Data, Combined with Once-Daily Inhaled Administration, Reinforce TPIP's Potential to Become the Prostanoid of Choice for Patients with PAH–
–Insmed to Host Investor Call

Insmed (INSM) PT Raised to $161 at Wells Fargo

Wed, 15 Jul 2026 06:52:07 -0400
Wells Fargo analyst Ben Burnett raised the price target on Insmed (NASDAQ: INSM) to $161.00 (from $160.00) while maintaining a Overweight rating.

Form 4 INSMED Inc For: Jul 09 Filed by: Lewis William

Fri, 10 Jul 2026 16:03:00 -0400
si-local-file:///var/storage/secattach/20260710/26757326.html

Form 4 INSMED Inc For: Jul 09 Filed by: Lewis William

Fri, 10 Jul 2026 16:03:00 -0400
si-local-file:///var/storage/secattach/20260710/26757326.html

Form 144 INSMED Inc Filed by: Lewis William

Thu, 09 Jul 2026 16:30:00 -0400
si-local-file:///var/storage/secattach/20260709/26753554.html

Form 144 INSMED Inc Filed by: Lewis William

Thu, 09 Jul 2026 16:30:00 -0400
si-local-file:///var/storage/secattach/20260709/26753554.html

Form 4 INSMED Inc For: Jul 06 Filed by: Flammer Martina M.D.

Wed, 08 Jul 2026 16:03:00 -0400
si-local-file:///var/storage/secattach/20260708/26747510.html

Form 4 INSMED Inc For: Jul 06 Filed by: Flammer Martina M.D.

Wed, 08 Jul 2026 16:03:00 -0400
si-local-file:///var/storage/secattach/20260708/26747510.html

Form 144 INSMED Inc Filed by: Flammer Martina M.D.

Mon, 06 Jul 2026 16:20:00 -0400
si-local-file:///var/storage/secattach/20260706/26735797.html

Form 144 INSMED Inc Filed by: Flammer Martina M.D.

Mon, 06 Jul 2026 16:20:00 -0400
si-local-file:///var/storage/secattach/20260706/26735797.html

Palvella Therapeutics adds Matt Pauls to its board of directors

Tue, 30 Jun 2026 07:30:35 -0400

Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.

Pauls brings more than 25 years of biopharmaceutical industry experience. Since 2020, he has served as chair of the board and chief executive officer of Savara Inc. (Nasdaq: SVRA), a clinical-stage company focused on rare respiratory diseases. From 2014 to 2019, he was president, CEO, and a board member of Strongbridge Biopharma (formerly Nasdaq: SBBP), which was later acquired by Xeris Pharmaceuticals. At Strongbridge, he led the company's Nasdaq initial public offering and oversaw commercialization of